Ketorolac Ophthalmic

Introduction Overview

Generic Name

ketorolac ophthalmic

Brand Name

Acular, Acular LS, Acuvail, Acular PF

Dosage Form

ophthalmic solution (0.4%, 0.45%, 0.5%)

Drug Class

Ophthalmic anti-inflammatory agents

Pharmacokinetics

Absorption: Ketorolac ophthalmic solution is administered topically to the eye. Upon instillation, it achieves therapeutic concentrations in the aqueous humor and ocular tissues by penetrating the cornea. Systemic absorption is minimal due to topical delivery; however, small amounts may enter systemic circulation through conjunctival and nasolacrimal mucosa absorption. The onset of action occurs within minutes post-application, with peak ocular concentrations generally achieved rapidly, providing prompt relief of inflammation and pain.

Distribution: Once absorbed locally in the eye, ketorolac distributes mainly within ocular tissues, including the cornea, conjunctiva, aqueous humor, and iris. Due to its hydrophobic nature, ketorolac partitions into lipid-rich ocular membranes. Systemic distribution is negligible given the low plasma concentration resultant from topical administration. Therefore, systemic side effects are rare. Distribution to non-ocular tissues is minimal, reducing systemic exposure risk.

Metabolism: Ketorolac undergoes limited metabolism in ocular tissues. Systemically absorbed ketorolac, although minimal, is extensively metabolized in the liver predominantly via hepatic hydroxylation and conjugation pathways to inactive metabolites. These metabolites have no pharmacological activity. Ocular metabolism is not well characterized but is considered minimal given the local, topical administration route.

Elimination: Metabolites of ketorolac that enter systemic circulation are eliminated primarily via renal excretion. The systemic half-life of ketorolac is approximately 4 to 6 hours. Ocular clearance occurs through tear drainage and systemic absorption. The topical application ensures rapid elimination from the ocular surface via nasolacrimal drainage, requiring repeated dosing to maintain therapeutic levels. Renal excretion of inactive metabolites completes the elimination process systemically, ensuring minimal accumulation.

Dosage Forms

Available Dosage Forms: Ketorolac ophthalmic is formulated as an ophthalmic solution available in three concentrations: 0.4%, 0.45%, and 0.5%.

Dosages for Adults and Adolescents: For corneal refractive surgery-associated pain and burning/stinging, the 0.4% ophthalmic solution is instilled one drop into the operated eye(s) four times daily for up to four days postoperatively. For postoperative ocular inflammation following cataract surgery, two dosing regimens exist: 0.45% solution instilled twice daily beginning one day before surgery and continuing for two weeks postoperatively, or 0.5% solution instilled four times daily starting 24 hours post-surgery and continuing for two weeks. For seasonal allergic conjunctivitis, the 0.5% solution is administered as one drop in the affected eye(s) four times daily.

Specific Patient Populations: Pediatric patients aged 2 years and older may use the 0.5% ophthalmic solution four times daily for allergic conjunctivitis and postoperative inflammation following cataract surgery. For corneal refractive surgery, children aged 3 years and older may use the 0.4% solution four times daily for up to four days. Patients using ketorolac ophthalmic should avoid contact lenses during treatment. No dose adjustments are explicitly recommended for elderly patients, but caution is advised due to potential increased susceptibility to adverse ocular effects. Use in pregnant or breastfeeding women should be under medical supervision as systemic exposure and effects remain unclear.

Mechanism Of Action

Ketorolac ophthalmic is a nonsteroidal anti-inflammatory drug (NSAID) that exerts its pharmacologic effect primarily through the inhibition of cyclooxygenase (COX) enzymes, COX-1 and COX-2. These enzymes catalyze the conversion of arachidonic acid to prostaglandins and thromboxanes, which are mediators of inflammation, pain, and fever. By inhibiting COX activity, ketorolac decreases the synthesis of prostaglandins, leading to reduced inflammation and associated ocular symptoms.

At the cellular level, ketorolac penetrates ocular tissues post topical administration, exerting its effect by blocking prostaglandin production within the cornea, conjunctiva, and anterior chamber. This reduction in prostaglandin levels decreases vasodilation and vascular permeability, resulting in diminished edema, redness, and discomfort. The inhibition of prostaglandin-mediated sensitization of nociceptors also contributes to its analgesic efficacy in ocular pain.

Biochemically, ketorolac competitively binds to the active site of COX enzymes, outcompeting arachidonic acid substrate. This blockade prevents the downstream formation of prostaglandin H2, the precursor of various pro-inflammatory prostanoids. Compared to corticosteroids, ketorolac does not affect gene transcription or broader immunosuppressive pathways, which results in fewer systemic effects and less risk for infection progression.

Clinically, ketorolac ophthalmic's mechanism is valuable in addressing ocular inflammation post-surgery (e.g., cataract or corneal refractive surgery) and allergic conjunctivitis by targeting the essential biochemical mediators driving inflammation and pain. Extensive clinical trials have demonstrated its efficacy and safety profile in reducing postoperative inflammation and ocular itching with a favorable tolerability compared to corticosteroids. Research also indicates that ketorolac provides analgesia without the increased risk of elevated intraocular pressure associated with steroid use, making it a preferred option in specific patient populations.

Pharmacological Actions

Nonselective inhibition of cyclooxygenase enzymes (COX-1 and COX-2), leading to decreased prostaglandin synthesis.
Anti-inflammatory action through reduction of ocular tissue edema, hyperemia, and leukocyte infiltration.
Analgesic effect by decreasing prostaglandin-mediated sensitization of ocular nociceptors, relieving pain and burning sensations.
Reduction of ocular itching in allergic conjunctivitis by diminishing inflammatory mediators.
Minimal systemic absorption reduces risk of systemic side effects compared to oral NSAIDs.
No significant immunosuppressive effects, thereby maintaining immune defense in ocular tissues.
Rapid onset of action following topical administration, allowing timely control of ocular inflammation.
Maintains intraocular pressure without steroid-induced elevation, reducing risk of glaucoma development.
Effective in postoperative inflammation management, preventing complications such as cystoid macular edema.
Improves patient comfort and surgical outcomes by managing postoperative ocular symptoms.
Exhibits ocular tissue penetration sufficient to reach therapeutic concentrations in anterior chamber.
Does not interfere with wound healing when used as directed, although prolonged use may impact corneal repair.
Suitable for use in pediatric populations aged 2 years and older with established safety data.
Compatible with other ophthalmic agents if separated by appropriate dosing intervals.
Provides an alternative to corticosteroids in patients with contraindications or steroid-induced complications.

Therapeutic Or Clinical Uses

Relief of ocular itching caused by seasonal allergic conjunctivitis.
Reduction of pain, swelling, and burning or stinging following cataract surgery.
Management of inflammation and pain after corneal refractive surgery.
Temporary treatment of ocular inflammation associated with various ocular surgeries.
Adjunctive therapy to improve patient comfort post ophthalmic surgical procedures.
Alternative to corticosteroids for patients at risk of steroid-induced intraocular pressure elevation.
Off-label use in other inflammatory eye conditions as determined by ophthalmologist.
Pediatric use for allergic conjunctivitis and postoperative inflammation in children aged 2 years and older.
Prevention of postoperative cystoid macular edema in susceptible patients.
Treatment of ocular discomfort due to seasonal environmental allergens.
Reduction of postoperative photophobia and ocular irritation.
Use in patients intolerant to steroid eye drops needing anti-inflammatory therapy.
Short-term management of ocular symptoms with minimal systemic side effects.
Component of multimodal therapy regimens in ophthalmic postoperative care.
Benefit in reducing topical corticosteroid dosage or duration in ocular inflammation management.

Side Or Adverse Effects

Mild to moderate eye burning, stinging, or irritation upon instillation.
Transient blurred vision immediately following drop application.
Watery eyes or increased lacrimation.
Swelling or puffiness of the eyelids.
Headache as a systemic mild side effect.
Severe burning, stinging, or itching indicative of ocular hypersensitivity.
Delayed wound healing or non-healing corneal epithelial defects with prolonged use.
Eye pain, redness, or increased tearing indicating possible ocular surface damage.
White patches on the eyes potentially signifying corneal deposits or ulceration.
Crusting or discharge suggestive of secondary eye infection.
Increased sensitivity to light (photophobia) post-application.
Allergic reactions, including hives or swelling of facial areas in rare cases.
Potential exacerbation of dry eye syndrome symptoms.
Rare incidence of corneal thinning or melts with extended therapy duration.
Transient foreign body sensation in the eyes following drop administration.

Precautions

Avoid use in patients with known allergy to ketorolac or other NSAIDs.
Use cautiously in patients with bleeding or blood clotting disorders due to potential local bleeding risk.
Inform physician if patient has glaucoma, dry eye syndrome, or diabetes prior to use.
Avoid concurrent use with contact lenses unless approved by physician.
Monitor for signs of delayed corneal healing or non-healing wounds during therapy.
Do not use beyond recommended duration to minimize risk of ocular surface damage.
Avoid contamination of the dropper tip to prevent serious eye infections.
Exercise caution in pediatric patients and use only as directed by ophthalmologist.
Not recommended for use in children under 2 years of age due to lack of safety data.
Pregnant and breastfeeding women should consult a healthcare provider before use.
Discontinue immediately if signs of allergic reaction or severe ocular adverse effects occur.
Avoid mixing with other ophthalmic medications by allowing at least 10 minutes between applications.
Patients with a history of NSAID hypersensitivity should be carefully evaluated before use.
Use with caution in patients prone to dry eye or ocular surface disorders.
Instruct patients on proper administration technique to minimize contamination and optimize efficacy.

Warnings

Serious ocular adverse reactions including severe burning, stinging, or eye pain may occur.
Prolonged use can result in serious damage to eyesight, including corneal complications.
Do not use if the solution changes color or contains particulate matter.
Avoid use in patients with allergy to any component or other NSAIDs to prevent hypersensitivity reactions.
Ensure proper disposal of single-use vials to prevent contamination and infection.
Avoid use in the presence of active ocular infections or corneal epithelial defects.
Discontinue use and seek medical attention if symptoms of eye infection or allergy develop.
Patients should be advised not to touch the dropper tip to any surface, including the eye.
Use with caution in conditions that may increase bleeding risk in ocular tissues.
Not to be used concurrently with contact lenses unless individually approved by the physician.
Warn patients about risks of photophobia and transient visual disturbances post-dose.
Avoid concomitant use with other topical NSAIDs to reduce toxicity risk.
Monitor ocular pressure to prevent unnoticed adverse impact on glaucoma patients.
Store medication at room temperature away from heat and moisture; do not freeze.
Emergency medical help should be obtained if signs of anaphylaxis or severe allergic reactions occur.

Contraindication

Known hypersensitivity or allergy to ketorolac or other NSAIDs.
History of bronchospasm, urticaria, or allergic reactions associated with aspirin or other NSAIDs.
Presence of active corneal epithelial damage or ocular infections.
Use in patients with bleeding disorders affecting ocular tissues.
Patients with late-stage pregnancy due to potential NSAID effects on fetal cardiovascular system (caution based on systemic exposure).
Avoid use if solution is discolored or contains foreign particles due to risk of infection.
Contraindicated in patients with hypersensitivity reactions to any component of the ophthalmic formulation.
Use in children under the age of 2 years is not recommended due to lack of safety and efficacy data.
Avoid use in patients with history of NSAID-induced angioedema or anaphylaxis.
Contraindicated if patient has active conjunctival or corneal infections.

Drug Interactions

Minimal systemic absorption minimizes significant drug interactions.
Concomitant use with other topical ophthalmic NSAIDs may increase risk of ocular toxicity.
Potential additive ocular irritation if used with multiple topical eye medications; allow at least 10 minutes between instillations.
Concurrent use with systemic anticoagulants like warfarin may increase bleeding risk; monitor closely.
Avoid use with other NSAIDs systemically or topically to prevent additive adverse effects.
No significant interactions reported with commonly used ophthalmic corticosteroids; however, staggered dosing recommended.
Possible interaction with ocular antihypertensives; monitor intraocular pressure.
No established interactions with herbal supplements, but caution advised due to potential bleeding risks.
Topical ocular absorption is generally low; thus, systemic drug interactions are unlikely but not impossible.
Patients should inform their healthcare providers about all medications to avoid potential interactions.
Ketorolac ophthalmic does not interfere with oral contraceptives or hormonal therapies.
No known interactions with systemic antibiotics; however, administer with appropriate timing to avoid dilution effects.
Combination with other irritant ophthalmic agents could exacerbate eye discomfort.
Interactions with other systemic NSAIDs may potentiate systemic side effects; caution advised.
No significant impact on metabolism or transport of concomitant drugs due to localized ocular administration.

Preparations Of The Drug

Ketorolac ophthalmic solution 0.4%
Ketorolac ophthalmic solution 0.45%
Ketorolac ophthalmic solution 0.5%
Available in multi-dose bottles and single-use vials for sterile administration.
Formulated as a clear to slightly opalescent, colorless to pale yellow aqueous solution.
Preservative-free formulations available (e.g., Acular PF) for patients sensitive to preservatives.
Stable at room temperature; do not freeze. Store away from light and moisture.
Packaged in dropper bottles or sealed foil pouches for single-use vials.
Some brands include Acular, Acular LS, Acuvail, and Acular PF with varying concentrations.
Single-use vials intended for one-time use in one eye to prevent contamination risk.
Multi-dose bottles feature a sterile dropper tip designed to reduce microbial contamination.
Formulations are isotonic, pH balanced for ocular comfort and stability.
Manufactured under sterile conditions following FDA regulations for ophthalmic products.
Accompanying patient information leaflets include detailed instructions on use, storage, and disposal.
Available by prescription only, requiring proper medical supervision for use.